Extended Data Figure 8. Nuclear accumulation of β-catenin in osteoblasts and increased Notch signaling in 38.3 % of patients with MDS/AML; and identification of underlying pre-AML conditions by nuclear localization of β-catenin in osteoblasts.

a-f, Double immunofluorecsence staining with β-catenin and Runx2 in osteoblasts from bone marrow biopsies from 6 MDS/AML patients harboring nuclear accumulation of β-catenin in osteoblasts and showing nuclear accumulation of Hey1 in the corresponding patients (60X). g-h, During screening assumed healthy controls, 2 individuals were identified with nuclear β-catenin in their osteoblasts. Re-evaluation showed underlying hematologic disorder, Case 1: MDS RAEB-1, Case 2: Jak2 positive myelofibrosis. g, Double immunofluorecsence staining with β-catenin and Runx2 in osteoblasts from bone marrow biopsies of the 2 cases (60X). h, β-catenin cellular localization in cases 1 and 2 with associated cytogenetic abnormalities. NL: normal cytogenetics. In the 4^th column percentages indicate osteoblasts with nuclear localization of β-catenin.